StockNews.AISignal intelligence
Summit Therapeutics Inc. · NASDAQ · Healthcare
Browse public SMMT signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Summit Therapeutics (SMMT) reported a narrower-than-expected Q2 loss but warned it lacks sufficient working capital for 12 months of planned operations, signaling a near-term funding hurdle. Jim Cramer described SMMT as a 'great spec,' potentially boosting sentiment despite liquidity concerns. The outcome could drive volatility until financing or partnership news materializes.
View signal analysisSummit reported Q2 results with $690.7M cash and ATM proceeds totaling $299.2M, extending financing runway. ASCO readouts for HARMONi-6 and updated HARMONi OS show cross-population survival benefits, and the FDA accepted the ivonescimab BLA with a PDUFA of 11/14/2026, creating near-term catalysts. A complete HARMONi-3 readout and continued international development support upside.
View signal analysisUpdated HARMONi data show stronger survival signals for Western patients (HR 0.76) with longer follow-up and no new safety issues. The trial supports Summit's FDA Biologics License Application, with a target action date of November 14, 2026. A positive decision could be a meaningful near-term catalyst for SMMT.
View signal analysisSummit reported updated global HARMONi OS analyses for ivonescimab in EGFR-mut NSCLC after third-gen TKIs. Western HR 0.76 aligns with Asian results, boosting OS signal. FDA accepted the BLA with a 11/14/2026 PDUFA date, underscoring potential near- to mid-term regulatory and commercial upside for SMMT.
View signal analysisSummit Therapeutics and Akeso reported Phase II AK112-206 results in first-line MSS metastatic colorectal cancer showing an ORR of 70.8% and a DCR of 100% when ivonescimab is combined with mFOLFOX6. The 20 mg/kg dose delivered more durable responses, with a 9-month PFS of 76.1% and a DOR of 79.1%. Safety remains manageable, with 20.4% serious TRAEs and no ivonescimab-related deaths, supporting further Phase III exploration via HARMONi-GI3.
View signal analysisSummit Therapeutics (SMMT) plans to showcase key overall survival data for ivonescimab at ASCO 2026. Additionally, with an FDA action date of November 14 for its biologics license application, investor attention is likely to focus on the drug's performance and upcoming trial results.
View signal analysis